Home › Research › Tau biomarkers
[Diagnostic value of tau in cerebrospinal fluid in alzheimer disease]
Hu Y, He S, Wang J.. Zhonghua yi xue za zhi, 2001-11-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To search for reliable and quantitative biochemical marker for diagnosis of Alzheimer disease. Methods ELISA-double enzyme amplification assay was used to detect the total tau and abnormally hyperphosphorylated (p-tau) in cerebrospinal fluid specimens of patients with Alzheimer disease (AD, N = 52, 30 from the Netherlands and 22 from Wuhan and Haikou, China), vascular dementia (VD, N = 46, 18 from the Netherlands and 28 from Haikou), and non-neurological disease (N = 37, 13 from the Netherlands and 24 from Haikou) and of normal elderly controls (N = 56, 26 from the Netherlands, and 30 from Wuan and Haikou). Results The measurement of CSF specimens from Netherlands Brain Bank showed that the levels of total tau and p-tau in CSF specimens of AD patients were significantly higher than those in CSF of patients with VD and non-dementia neurological disorders, and of age-matched non-
What this study adds
Evidence grade: Low
The record lists 52 participants. In this study, levels of total tau and p-tau in cerebrospinal fluid were significantly higher in Alzheimer's disease patients than in those with vascular dementia, other non-dementia neurological disorders, and age-matched controls. Reported effect size: 90.0%; 79.0%; 82.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hu, Y., He, S., & Wang, J. (2001). [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease]. Zhonghua yi xue za zhi.
Vancouver
Hu Y, He S, Wang J. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease]. Zhonghua yi xue za zhi. 2001. PMID: 11930632.
BibTeX
@article{hu2001-11930632,
author = {Hu, Y. and He, S. and Wang, J.},
title = {{[Diagnostic value of tau in cerebrospinal fluid in alzheimer disease]}},
journal = {Zhonghua yi xue za zhi},
year = {2001},
pmid = {11930632}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Methods ELISA-double enzyme amplification assay was used to detect the total tau and abnormally hyperphosphorylated (p-tau) in cerebrospinal fluid specimens of patients with Alzheimer disease (AD, N = 52, 30 from the Netherlands and 22 from Wuhan and Haikou, China), vascular dementia (VD, N = 46, 18 from the Netherlands and 28 from Haikou), and non-neurological disease (N = 37, 13 from the Netherlands and 24 from Haikou) and of normal elderly controls (N = 56, 26 from the Netherlands, and 30 from Wuan and Haikou).
- Results The measurement of CSF specimens from Netherlands Brain Bank showed that the levels of total tau and p-tau in CSF specimens of AD patients were significantly higher than those in CSF of patients with VD and non-dementia neurological disorders, and of age-matched non-neurological normal controls.
- With CSF tau > or = 370 pg/ml as the marker for diagnosis of AD, the sensitivity, specificity, reliability as well as differentiation rate of AD from VD were 90.0%, 79.0%, 82.8% and 66.7%, respectively.
- With CSF p-tau > or = 120 pg/ml as the marker for diagnosis of AD, the sensitivity, specificity, reliability as well as differentiation rate of AD from VD were 93.3%, 89.5%, 90.8%, and 83.3% respectively.
Why it matters
In this study, levels of total tau and p-tau in cerebrospinal fluid were significantly higher in Alzheimer's disease patients than in those with vascular dementia, other non-dementia neurological disorders, and age-matched controls. This supports the use of these cerebrospinal fluid markers to help distinguish Alzheimer's disease from other conditions, though the study does not address treatment or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants52
- Effect size90.0%; 79.0%; 82.8%
- Evidence strengthLow
How this study scored 33/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 30 of the 92 points we could judge it on, which is 33 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Zhonghua yi xue za zhi) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2001 — older than 20 years, still counted |
| Sample size | 1 / 4 | 52 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.2 citations a year over 27 year(s) since 2001 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Jianman Wang holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | Huazhong University of Science and Technology: institution h-index 934 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11930632) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 30 / 92 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 30 of the 92 points we could judge it on is 33 out of 100. |
| Total | 33 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.